MUDr. Martin Štork, Ph.D.
Assistant, Department of Internal Medicine, Hematology and Oncology
Phone: | +420 532 23 3517, 3603 |
---|---|
E‑mail: |
social and academic networks: |
---|
Total number of publications: 61
2021
-
Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice
BMC Cancer, year: 2021, volume: 21, edition: 1, DOI
-
Transformace IgM-MGUS do Waldenströmovy makroglobulinemie u 2 z 6 pacientů v průběhu léčby syndromu Schnitzlerové
Vnitřní lékařství, year: 2021, volume: 67, edition: 3, DOI
-
Urine immunofixation negativity is not necessary for complete response in intact immunoglobulin multiple myeloma: Retrospective real-world confirmation
International Journal of Laboratory Hematology, year: 2021, volume: 43, edition: 5, DOI
2020
-
Bortezomib retreatment is effective in relapsed multiple myeloma patients - real-life clinical practice data
Neoplasma, year: 2020, volume: 67, edition: 1, DOI
-
Diagnostic relevance of 18F-FDG PET/CT in newly diagnosed patients with monoclonal gammopathy of undetermined significance (MGUS): Single-center experience
Neoplasma, year: 2020, volume: 67, edition: 4, DOI
-
Primary refractory multiple myeloma: a real-world experience with 85 cases
LEUKEMIA & LYMPHOMA, year: 2020, volume: 61, edition: 12, DOI
2019
-
Bortezomib and Th alidomide Treatment Results in Newly Diagnosed Transplant-Ineligible Multiple Myeloma Patients are Comparable in Long-Term Follow-Up.
Klinická onkologie, year: 2019, volume: 32, edition: 6
-
Denosumab a bisfosfonáty u mnohočetného myelomu v roce 2019
Transfúze a hematologie dnes, year: 2019, volume: 25, edition: 4
-
MikroRNA u mnohočetného myelomu
Year: 2019, type: Conference abstract
-
Osteonekróza čelisti, atypické fraktury kostí a další méně časté nežádoucí účinky bisfosfonátů
Transfúze a hematologie dnes, year: 2019